Yale University

Contramed, LLC

Pasquale Patrizio

Patrick N Gutelius

Oleg Shikhman

Michael Gabriel Tal

Bob H Katz

Mark James DeBisschop

Mark DeBisschop

Michael G Tal

Dagan Wells

Oleg Shikman

An intrauterine device for applying pressure to the walls of the uterine cavity includes a resilient body having an elongated member which includes a first end and a second end which are resiliently biased away from each other. The first end of the elongated member includes a first leg having a first end and a second end. The second end of the elongated member includes a second leg having a first end and a second end. A connection member is positioned between the first end of the first leg and the first end of the second leg. A first plug member is secured at the second end of the first leg and a second plug member is secured at the first end of the second leg. The first and second plug members are shaped and dimensioned for bearing against the walls of the uterine cavity as the elongated member spreads outwardly with the first end and the second end moving apart. A method for preventing conception within the uterine cavity is also disclosed.

Intrauterine device

An intrauterine device for applying force to a wall of a uterus to promote contraception without blocking the fallopian tubes may include an elongate member formed of a resilient material and having a default expanded configuration and a spring portion disposed approximately at a midpoint between two ends of the elongate member. The IUD may also include two tissue contact members, one tissue contact member disposed at one of the two ends of the elongate member and the other tissue contact member disposed at the other end. The tissue contact members may generate a laterally directed force against the wall of the uterus when the intrauterine device assumes its default expanded configuration.

Methods are provided for evaluating an oocyte for fertilization and implantation. For example, methods are provided for determining whether an oocyte expresses, or does not express, one or more of a group of markers identified as differently expressed between chromosomally normal and chromosomally abnormal oocytes. Also provided, for example, are methods for determining whether a cumulus cell expresses, or does not express, one or more of a group of markers identified as differently expressed between cumulus cells associated with chromosomally normal oocytes and cumulus cells associated with chromosomally abnormal oocytes. Methods are provided for the detection of marker expression of differentially expressed genes at the RNA level, as well as at the protein level.

Assessment of oocyte competence

Growing community of inventors

Guilford, CT, United States of America

Pasquale Patrizio